16583-08-7

Usage

Chemical Properties

light yellow crystalline powder

InChI:InChI=1/C7HF4NO4/c8-2-1(7(13)14)6(12(15)16)5(11)4(10)3(2)9/h(H,13,14)/p-1

Upstream product

• 16583-07-6 2-NO₂-C₆F₄C(O)NH₂ 
• 1201-31-6 2,3,4,5-tetrafluorobenzoic acid 
• 5580-79-0 2,3,4,5-tetrafluoro-1-nitrobenzene 
• 5580-80-3 2,3,4,5-tetrafluoroaniline 
• 5580-81-4 2-Brom-3,4,5,6-tetrafluor-acet-anilid 
• 16582-99-3 2-NH₂-C₆F₄CN 
• 5580-82-5 2-bromo-3,4,5,6-tetrafluoroaniline 
• 16583-05-4 2-Nitrotetrafluorbenzonitril 
• 551-62-2 1,2,3,4-tetrafluorobenzene 

Downstream Products

• 103772-10-7 2,3,4,5-tetrafluoro-6-nitro-benzoyl chloride 
• 4920-62-1 2-(dimethylamino)-3,4,5,6-tetrafluorobenzoic acid 
• 1765-42-0 2-amino-3,4,5,6-tetrafluorobenzoic acid 
• 1322564-49-7 C₉H₈F₃N₃O₃ 
• 1322564-99-7 (S)-2-(1-(benzo[d][1,3]dioxol-5-ylmethyl)-5,7-difluoro-2-(3,4,5-trimethoxyphenyl)-1H-benzo[d]imidazol-6-ylamino)propanamide 
• 1322564-96-4 (S)-2-(1-(1-benzylpiperidin-4-yl)-5,7-difluoro-2-(3,4,5-trimethoxyphenyl)-1H-benzo[d]imidazol-6-ylamino)propanamide 
• 1322564-93-1 (S)-2-(1-cyclopentyl-5,7-difluoro-2-(3,4,5-trimethoxyphenyl)-1H-benzo[d]imidazol-6-ylamino)propanamide 
• 1322564-92-0 (S)-2-(1-(2-(cyclohex-1-en-1-yl)ethyl)-5,7-difluoro-2-(3,4,5-trimethoxyphenyl)-1H-benzo[d]imidazol-6-ylamino)propanamide 
• 1322564-91-9 (S)-2-(1-(4-chlorophenethyl)-5,7-difluoro-2-(3,4,5-trimethoxyphenyl)-1H-benzo[d]imidazol-6-ylamino)propanamide 

Relevant academic research and scientific papers

An efficient synthesis of 3,5-dimethoxy-2,4-difluorobenzoic acid

3,5-Dimethoxy-2,4-difluorobenzoic acid, as a key intermediate for preparing an impurity of moxifloxacin, was synthesised from 2,3,4,5-tetrafluorobenzoic acid in moderate yield by nitration, methoxyl substitution, reduction of NO2, diazotisation and reduction. The structures of the intermediates and the target compound were identified and determined with IR, NMR and HRMS (ESI).

Synthesis and biological activity of 5-amino- and 5-hydroxyquinolones, and the overwhelming influence of the remote N1-substituent in determining the structure-activity relationship

A series of 5-amino- and 5-hydroxyquinolone antibacterials substituted at C7 with a select group of common piperazinyl and 3-aminopyrrolidinyl side chains was prepared. These 5-substituted derivatives were compared to the analogous 5-hydrogen compounds for antiinfective activity by using DNA gyrase inhibition, minimum inhibitory concentrations against a variety of bacteria, and in vivo efficacy in the mouse infection model. The influence on the structure-activity relationships of varied substituents at C8 (H, F, Cl) and N1 (ethyl, cyclopropyl, difluorophenyl) was also studied. The results showed that several of the structure-activity conclusions regarding side-chain bulk at C7, the effect of halogen at C8, and the effect of the C5-amino group were greatly influenced by the choice of the N1-substituent. Several outstanding broad spectrum quinolones were identified in this work. In particular, the spectrum and potency of the 7-piperazinyl quinolones could be greatly enhanced by the judicious choice of C5-, C8-, and N1-substitutents.